This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Testosterone Undecanoate and Quality of Life of Men and Spouses

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Meir Medical Center Identifier:
First received: December 23, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted

This study will be conducted as a prospective, single-center (multiple clinics), single-arm open phase IV study.

the study will follow hypogonadal patients, and aimed to confirm the hypothesis that testosterone undecanoate improves the patient satisfaction and quality of life, with parallel improvement in their spouses's quality of life and satisfaction. Each patient/spouse will serve as his own control.

Condition Intervention
Hypogonadism Drug: testosterone undecanoate

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Satisfaction and Quality of Life of Men and Spouses of Hypogonadal Men Treated With Injectable Testosterone Undecanoate

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • patient and spouse satisfaction an quality of life [ Time Frame: 28 weeks ]
    the outcome measure will be assessed with various validated questionnaires.

Estimated Enrollment: 80
Study Start Date: January 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Testosterone Undecanoate
treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
Drug: testosterone undecanoate
treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
Other Name: Nebido 1000mg

Detailed Description:

the study protocol will follow hypogonadal patients, who initiate treatment with testosterone undecanoate, given in accordance with the standard protocol.

Hypogonadal men eligible for treatment with testosterone undecanoate, who have not been treated with testosterone undecanoate within the last 6 months prior to enrollment, can be enrolled in the study. Patients who were treated with another testosterone formulation (eg. testosterone gel, testosterone enanthate injections) will require a 4 week wash-out period. Patients must be enrolled after the decision for treatment with testosterone undecanoate has been made.

Patients will be followed for an observation period of 28 weeks. Observations will be recorded at 3 consecutive visits, and will assess patient and spouse satisfaction and quality of life with validated questionnaires.

The study design is an intra-individual comparison. Each patient/spouse serves as his own control.

a laboratory test for total testosterone level will be required in the last visit. the need for concomitant phosphodiesterase-5 inhibitors use will also be recorded and analyzed.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
community based population of hypogonadal men, who are eligible and choose the treatment with testosterone undecanoate

Inclusion Criteria:

  • Hypogonadal patient age 40 to 80 who has newly been prescribed testosterone undecanoate.
  • The patient must be in a stable (>3 months) heterosexual relationship to be eligible for the study
  • Diagnosis of hypogonadism at the discretion of the physician, based on patient's symptoms and a laboratory evidence of T levels below 12 (symptomatic patients with borderline levels of 8.4 to 12 are also eligible for testosterone replacement therapy)
  • Wash-out of 6 months for testosterone undecanoate, 4 weeks for other testosterone formulations, before study entry.
  • Patient & spouse must be capable and willing to fill-in questionnaires to be enrolled in the study
  • Informed consent is required

Exclusion Criteria:

  • The standard contraindications and warnings of treatment with testosterone replacement therapy, and specifically testosterone undecanoate, must be followed. Contra-indications as copied from the product prescribing information are: androgen-dependent carcinoma of the prostate or of the male mammary gland; past or present liver tumors; hypersensitivity to the active substance or to any of the excipients
  • Men with desired paternity will be excluded
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01758029

Contact: uri gur, MD 972-54-7738384

Sponsors and Collaborators
Meir Medical Center
Principal Investigator: uri gur, MD Israel: Clalit Health Services
  More Information


Responsible Party: Meir Medical Center Identifier: NCT01758029     History of Changes
Other Study ID Numbers: NBD01
Study First Received: December 23, 2012
Last Updated: December 23, 2012

Keywords provided by Meir Medical Center:
quality of life
Testosterone Undecanoate

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on August 16, 2017